

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER Medical Holdings Limited
希瑪醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3309)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of the Company dated 20 May 2026 (the “**Announcement**”) in relation to the subscription for and acquisition of an aggregate of approximately 10.23% in the enlarged issued share capital of the Target Company (the “**Transactions**”). Unless otherwise defined, terms used herein shall have the same meaning as those defined in the Announcement.

The Company wishes to provide supplemental information regarding the Transactions as follows:

EXCLUSIVE RIGHTS OF USE OF DRUG CANDIDATE ZVS101E IN HONG KONG AND MACAU

As disclosed in the Announcement, one of the conditions precedent to the C-MER Series B Investment Agreement includes the passing of the relevant resolutions by the Target Company on the approval of the granting of the exclusive rights of use of ZVS101e in Hong Kong and Macau to the Group (the “**Exclusive Rights**”) and the directors (or such other designated persons) of the Target Company having been authorised to enter into a cooperation agreement or agreement of similar effect in a form satisfactory to the Company (the “**Relevant Resolutions**”). As of the date of this announcement, to the best knowledge of the Directors, the Relevant Resolutions have been passed. The Directors consider the grant of the Exclusive Rights is mutually beneficial to the Group and the Target Company. In particular, the Target Company is expected to benefit from such strategic cooperation in two aspects, (i) by leveraging the Group’s local support, to complete expedited registration of ZVS101e in Hong Kong through “1+” mechanism under the Department of Health of Hong Kong; and (ii) to conduct clinical trials to collect data from local patients and East Asian patients coming to Hong Kong for treatment, which in turn will support and expedite the market entry of ZVS001e in other markets.

As of the date of this announcement, the Group and the Target Company have not entered into any written agreement in relation to the grant of the Exclusive Rights and therefore there is a potential risk that the Exclusive Rights will not be granted ultimately. However, it is expected that the Group will enter into an legally binding agreement in relation to the grant of the Exclusive Rights (the “**Legally Binding Agreement**”) with the Target Company as one of such other documents requested by HK (International) Eye Care under the transaction documents, the execution and delivery of which constitute one of the conditions precedent before the completion. The Legally Binding Agreement will stipulate (i) the grant of the Exclusive Rights on a perpetual basis upon the fulfillment of conditions precedent, namely the obtaining of the approval from NMPA and that of local authorities in Hong Kong and Macau; (ii) the revenue allocation to the Group will be no less favourable to the Group than any similar agreement entered into or to be entered into by the Target Company in relation to the application of ZVS101e, and (iii) any dispute arising out of or in connection with such agreement shall be referred to mediation at Hong Kong International Arbitration Centre (HKIAC) and in accordance with its then current mediation rules.

In the event no such Legally Binding Agreement is signed on or before the completion as one of the conditions precedent, HK (International) Eye Care is entitled to not to proceed with the completion of the C-MER Series B Investment Agreement at the Group’s sole discretion. In view of the potential benefits to the Group derived from the grant of the Exclusive Rights, HK (International) Eye Care, despite its contractual right to waive such condition precedent, has no present intention to waive such condition precedent and is in the process of finalizing the Legally Binding Agreement.

In the event that no license agreement on the Exclusive Rights is entered into solely attributable to the fault of the Target Company, HK (International) Eye Care will consider the pursuit of legal actions to recover any of its losses as appropriate.

The Company will make further announcement and other disclosure requirement when the license agreement is entered into as required by the Listing Rule.

INFORMATION ON THE TRANSFERORS

As of the date of this announcement, Wedo Capital is owned by the following entities/ individuals:

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
Jiangsu Bioperfectus Technologies Co., Ltd. (江蘇碩世生物科技股份有限公司) ⁽¹⁾	Limited partner	16.0%
Qingdao Ocean Development Group Co., Ltd. (青島海洋發展集團有限公司) ⁽²⁾	Limited partner	9.6%

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
Shenzhen Youyi Financial Service Co., Ltd. (深圳優益金融服務有限公司) ⁽³⁾	Limited partner	9.0%
Bosera Capital Management Co., Ltd. (博時資本管理有限公司) ⁽⁴⁾	Limited partner	6.0%
Wu Anhua (吳安華)	Limited partner	6.0%
Hu Guoquan (胡國泉)	Limited partner	6.0%
Zhao Hongfei (趙鴻飛)	Limited partner	6.0%
Zhejiang Free Trade Zone Jingyuan Investment Partnership (Limited Partnership) (浙江自貿區靜遠投資合夥企業(有限合夥)) ⁽⁵⁾	Limited partner	4.0%
Sun Xu (孫序)	Limited partner	4.0%
Zheng Xiaodong (鄭曉東)	Limited partner	4.0%
Liaoning Chengda Biotechnology Co., Ltd. (遼寧成大生物股份有限公司) ⁽⁶⁾	Limited partner	4.0%
Nanjing Jiawei Venture Capital Partnership (Limited Partnership) (南京佳葦創業投資合夥企業(有限合夥)) ⁽⁷⁾	Limited partner	4.0%
Xia Nan (夏楠)	Limited partner	3.0%
Tu Yafang (塗雅芳)	Limited partner	2.0%
Mu Di (牟頤)	Limited partner	2.0%
Wang Dequan (王德權)	Limited partner	2.0%
Wang Bing (王兵)	Limited partner	2.0%
Dong Xiaojie (東小傑)	Limited partner	2.0%
Luo Ning (羅凝)	Limited partner	2.0%
Shanghai Yihumi Business Consulting Studio (上海一斛米商務諮詢工作室) ⁽⁸⁾	Limited partner	2.0%
Shanghai Hengfeng Investment Management Co., Ltd. (上海恒逢投資管理有限公司) ⁽⁹⁾	Limited partner	2.0%
Shanghai Jiangying Investment Management Co., Ltd. (上海將應投資管理有限公司) ⁽¹⁰⁾	Limited partner	2.0%
Nanjing Wedo Yunshi Management Consulting Partnership (Limited Partnership) (南京葦渡雲石管理諮詢合夥企業(有限合夥)) ⁽¹¹⁾	General partner	0.4%

Notes:

1. Jiangsu Bioperfectus Technologies Co., Ltd. is a company whose shares are listed on the Shanghai Stock Exchange, stock code: 688399.
2. Qingdao Ocean Development Group Co., Ltd. is ultimately and wholly owned by State-owned Assets Supervision and Administration Commission of the Qingdao Municipality People's Government (青島市人民政府國有資產監督管理委員會).
3. Shenzhen Youyi Financial Service Co., Ltd. is owned as to 80% by Guo Zhongbin (郭忠斌) and 20% by Chen Sha (陳莎).
4. Bosera Capital Management Co., Ltd. is ultimately owned as to 49% by China Merchants Securities Co., Ltd. (招商證券股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange, stock code: 600999 and the Hong Kong Stock Exchange, stock code: 6099) and 25% by China Great Wall Asset Management Co. Ltd. (中國長城資產管理股份有限公司), which is State-owned.
5. Zhejiang Free Trade Zone Jingyuan Investment Partnership (Limited Partnership) is ultimately owned as to 50.0% by Qin Zhi (秦致), 25.67% by Li Qiumei (李秋梅) and 24.33% by Geng Hao(耿灝) respectively.
6. Liaoning Chengda Biotechnology Co., Ltd. is a company whose shares are listed on Shanghai Stock Exchange, stock code: 688739.
7. Nanjing Jiawei Venture Capital Partnership (Limited Partnership) is ultimately owned as to 80.0% by Jin Guanghe (金光赫) and 20.0% by Xu Yongfeng (許永鋒).
8. Shanghai Yihumi Business Consulting Studio is ultimately wholly owned by Chen Xuan (陳翺).
9. Shanghai Hengfeng Investment Management Co., Ltd. is ultimately owned as to 90.0% by Li Zheng (李崢) and 10.0% by Zhou Xi (周西).
10. Shanghai Jiangying Investment Management Co., Ltd. is ultimately owned as to 90.0% by Zhou Xi (周西) and 10.0% by Li Zheng (李崢).
11. For details of Nanjing Wedo Yunshi Management Consulting Partnership (Limited Partnership), please refer to the announcement of the Company dated 20 May 2026.

As of the date of this announcement, Suzhou Jingshuo is owned by the following entities/ individuals:

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
Beijing Jinghao Technology Services Co., Ltd. (北京景濤科技服務有限公司) ^(Note)	General partner	1.0%
Li Heng (李衡)	Limited partner	27.0%
Chen Dong (陳棟)	Limited partner	9.0%
Pang Yajuan (龐玉娟)	Limited partner	9.0%
Qu Xiaopeng (屈曉鵬)	Limited partner	9.0%
Wu Yun (吳雲)	Limited partner	9.0%
Yang Zhan (楊展)	Limited partner	9.0%
Guo Baikuan (郭柏寬)	Limited partner	9.0%
Geng Chongyang (耿重陽)	Limited partner	9.0%
Su Zheng (蘇錚)	Limited partner	9.0%

Note: Beijing Jinghao Technology Services Co., Ltd. is wholly owned by Hao Jing (郝婧).

As of the date of this announcement, Guangzhou Heying is owned by the following entities/ individuals:

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
Qingdao Ririshun Huitong Investment Management Co., Ltd. (青島日日順匯通投資管理有限公司) ⁽¹⁾	Limited partner	49.0%
Xinyu Tongrong Gongxing Investment Management Partnership (Limited Partnership) (新余同榮共興投資管理合夥企業(有限合夥)) ⁽²⁾	Limited partner	25.0%
Guangzhou Industrial Investment Fund Management Co., Ltd. (廣州產業投資基金管理有限公司) ⁽³⁾	Limited partner	20.0%
Shenzhen Tongchuang Haoshun Investment Consulting Co., Ltd. (深圳同創昊順投資諮詢有限公司) ⁽⁴⁾	General partner	5.0%
Shenzhen Cowin Asset Management Co., Ltd. (深圳同創偉業資產管理股份有限公司) ⁽⁵⁾	Limited partner	1.0%

Notes:

1. Qingdao Ririshun Huitong Investment Management Co., Ltd. is ultimately controlled by Haier Smart Home Co., Limited, a company whose shares are listed on Shanghai Stock Exchange, stock code:600690, and the Main Board of the Stock Exchange, stock code: 6690).
2. Xinyu Tongrong Gongxing Investment Management Partnership (Limited Partnership) is owned as to 90.0% by Deng Qizhi (鄧奇志) and 10.0% by Wang Haibo (王海波).
3. Guangzhou Industrial Investment Fund Management Co., Ltd. is owned as to 90.0% by the State-owned Assets Supervision and Administration Commission of the Guangzhou Municipality People's Government (廣州市人民政府國有資產監督管理委員會) and 10.0% by Guangzhou Municipal Finance Bureau (廣州市財政廳).
4. For details of Shenzhen Tongchuang Haoshun Investment Consulting Co., Ltd., please refer to the announcement of the Company dated 20 May 2026.
5. Shenzhen Cowin Asset Management Co., Ltd. is a company whose shares are quoted on the NEEQ, stock code: 832793.

As of the date of this announcement, Hetang Innovation Fund is owned by the following entities/individuals:

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
Beijing Technology Innovation Fund (Limited Partnership) (北京市科技創新基金(有限合夥)) ("Beijing Technology Innovation Fund") ⁽¹⁾	Limited partner	40.0%
CCB Pilot Strategic Emerging Industry Development Fund (Limited Partnership) (建信領航戰略性新興產業發展基金(有限合夥)) ("CCB Strategic Emerging Industry Fund") ⁽²⁾	Limited partner	15.0%
Jiangsu Maotai Venture Capital Co., Ltd. (江蘇茂泰創業投資有限公司) ⁽³⁾	Limited partner	13.0%
Beijing Saisheng Pharmaceutical Co. (北京賽升藥業股份有限公司) ⁽⁴⁾	Limited partner	10.0%
Beijing Daxing Development Guidance Fund (Limited Partnership) (北京市大興發展引導基金(有限合夥)) ⁽⁵⁾	Limited partner	9.0%

Name of partners(s)	Nature of the partnership	Percentage of partnership interest (%)
CSPC NBP Pharmaceutical Co., Ltd. (石藥集團恩必普藥業有限公司) ⁽⁶⁾	Limited partner	4.0%
Beijing Hetang Qingjian Biotechnology Co., Ltd. (北京荷塘清健生物科技有限公司) ⁽⁷⁾	General partner	3.0%
Taizhou City Industrial Investment Fund (Limited Partnership) (泰州市產業投資基金(有限合夥)) ⁽⁸⁾	Limited partner	3.0%
Taizhou City Shengxin Venture Capital Management Co., Ltd. (泰州市盛鑫創業投資管理有限公司) ⁽⁹⁾	Limited partner	3.0%

Notes:

1. Beijing Technology Innovation Fund has a wide investors base, and is ultimately owned as to 49.33% by Beijing Municipal People's Government State-owned Assets Supervision and Administration Commission (北京市人民政府國有資產監督管理委員會), 15% by China Insurance Company Limited (中國人壽保險股份有限公司) ("China Insurance", a company whose shares are listed on the Shanghai Stock Exchange, stock code: 601628 and Hong Kong Stock Exchange, stock code: 2628) and 9.0% by Ministry of Finance of the PRC (中華人民共和國財政部), with the remaining ultimate beneficial owner each holding less than 10%.
2. CCB Strategic Emerging Industry Fund has a wide investors base, and is ultimately owned as to (i) 30% by Shenzhen Municipal Bureau of Finance (深圳市財政局), (ii) 12.32% by CCB Life Insurance Co., Ltd. (建信人壽保險股份有限公司) (which in turn is owned as to 51% by China Construction Bank Corporation (中國建設銀行股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange, stock code: 601939 and Hong Kong Stock Exchange, stock code: 0939), (iii) 12.32% by CETC Investment Holding Co., Ltd. (中電科投資控股有限公司) (which in turn is ultimately wholly owned by State-owned Assets Supervision and Administration Commission of the State Council), (iv) 10.27% by China Post Life Insurance Co., Ltd. (中郵人壽保險股份有限公司) (which in turn is ultimately owned as to 75% by the State Council of the PRC and 25% by AIA Group Limited (友邦保險控股有限公司), a company whose shares are listed on the Hong Kong Stock Exchange, stock code: 1299) and (v) 8.22% by China Insurance, with the remaining ultimate beneficial owner each holding less than 5%.
3. Jiangsu Maotai Venture Capital Co., Ltd. is ultimately wholly owned by Taizhou Municipal State-owned Assets Supervision and Administration Commission (泰州市政府國有資產監督管理委員會).
4. Beijing Saisheng Pharmaceutical Co. is a company whose shares are listed on the Shenzhen Stock Exchange, stock code: 300485.

5. Beijing Daxing Development Guidance Fund (Limited Partnership) is ultimately wholly owned by Beijing Daxing District People's Government State-owned Assets Supervision and Administration Commission (北京市大興區人民政府國有資產監督管理委員會).
6. CSPC NBP Pharmaceutical Co., Ltd. is a subsidiary of CSPC Pharmaceutical Group Limited, a company whose shares are listed on the Hong Kong Stock Exchange, stock code: 1093.
7. Beijing Hetang Qingjian Biotechnology Co., Ltd. (北京荷塘清健生物科技有限公司) has a wide investors base, and is ultimately controlled as to approximately 50.1% by Yang Hongru (楊宏儒), approximately 14.4% by Zhang Shanliang (張善良), 10.0% by Beijing Tsinghua Industrial Development Research Institute (北京清華工業開發研究所) (which is a business unit (事業單位) jointly established and managed by the Beijing Municipal People's Government and Tsinghua University, tasked with the mission of transforming and industrializing scientific and technological achievements of Tsinghua University in Beijing), approximately 8.6% by Qiu Qing (邱慶), 8.0% by Ma Jianan (馬嘉楠), with the remaining partners each holding less than 5.0%.
8. Taizhou City Industrial Investment Fund (Limited Partnership) has a wide investors base, and is ultimately owned as to 68.43% by Taizhou Municipal Government State-owned Assets Supervision and Administration Commission (泰州市政府國有資產監督管理委員會).
9. Taizhou City Shengxin Venture Capital Management Co., Ltd. is ultimately owned as to 84.25% by Taizhou Jiangyan District People's Government State-owned Assets Supervision and Administration Office (泰州市姜堰區人民政府國有資產監督管理辦公室) and 15.75% by Taizhou Municipal Government State-owned Assets Supervision and Administration Commission (泰州市政府國有資產監督管理委員會).

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the counterparties under the Share Purchase Agreements and the C-MER Series B Investment Agreement and their respective ultimate beneficial owners are Independent Third Parties of the Company.

By order of the Board
C-MER Medical Holdings Limited
Ms. LI Xiaoting

Vice Chairman, Executive Director and Chief Executive Officer

Hong Kong, 30 June 2026

As at the date of this announcement, the Board comprises its chairman and independent non-executive Director, Dr. Rex AU YEUNG Pak-kuen; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.